---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-023859"
form_type: "8-K"
ticker: "PURE"
cik: "0001006028"
company_name: "PURE BIOSCIENCE, INC."
filed_at: "2024-06-14T23:59:59+00:00"
generated_at: "2026-06-01T04:14:07.769545+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PURE Bioscience Q3 net product sales $440K, net loss $857K; loss per share ($0.01)

## Summary
- Net product sales $440,000 for Q3 FY2024, up 8% vs $406,000 in prior-year quarter.
- Net loss $857,000; narrower than $876,000 in Q3 FY2023; net loss per share unchanged ($0.01).
- For the nine months ended April 30, 2024, net product sales $1,483,000, net loss $2,594,000.
- Company transitioning to distributor model; new Tier Pricing Agreement developed for distributor margins.
- Social media platform engagement up 167% in past 90 days; followers up nearly 70%.

## SEC filing metadata
- accession: 0001493152-24-023859
- form_type: 8-K
- ticker: PURE
- cik: 0001006028
- company_name: PURE BIOSCIENCE, INC.
- filed_at: 2024-06-14T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1006028/000149315224023859/0001493152-24-023859-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1006028/000149315224023859/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-023859
- JSON: https://secwatch.observer/filing/0001493152-24-023859.json
- Plain text: https://secwatch.observer/filing/0001493152-24-023859.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.